<prompt> Treatment of AIDS include3 Reverse transcriptase inhibitors2 Reverse transcriptase inhibitors 1 Protease inhibitors2 Reverse transcriptase inhibitors 2 Protease inhibitors3 Reverse transcriptase inhibitors 1 Protease inhibitors  <response>: 2 Reverse transcriptase inhibitors 1 Protease inhibitors 1124-H 1197-1201-300-CMDT-09 1190- H17thCurrently licenced drugs for the treatment of HIV infections fall into three categories: those that inhibit the viral reverse transcriptase enzyme: those that inhibit the viral protease enzymes, and those that interfere with viral entry 1124-HReverse transcriptase inhibitors includei Nucleoside analogues - Zidovudine, Zalcitabine, Didanosine, Zalcitabine, Stavudine, Lamivudine, abacavir, and emtricibineii Nucleotide analogues - tenofovirNon-nucleoside reverse transcriptase inhibitors - nevirapine, delavirdine and efavirenzProtease inhibitors PIs Saquinavir, Ritonavir, Indinavir, Nelfinavir, Amprenavir, Fosamprenavir, Lopinavir, AtazanavirEntry inhibitors Fusion inhibitors - Enfuvirtide The combination of Zidovudine, Lamivudine and indinavir was the first triple combination shown to have a profound effect on HIV replication 1134-HSymptomatic HIV disease or asymptomatic disease and CD4 200pL or asymptomatic disease and special circumstances Best first line treatmentCombivirEfavirenz Common altemativeregimens once a day regimens Tenofovir Lamivudine Efavirenz Tenofovir Efavirenz Afazanavir Ritonavir Intolerance to regimen Progression of disease or viral load does not decrease by 0.5 log with initiation of treatment or increase of viral load by 0.5 log while on treatmentLow pill burden regimens Combivir Neviripine Trizivir Change to alternative first line regimens High potency regimens Perform resistance testing and change to a regimen with three drugs to which the patient is not resistant. If possible Combivir Lopinavir withRitonavir Approach to antiretroviral therapy 